Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
194 participants
INTERVENTIONAL
2020-10-16
2024-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening
NCT04557423
Early Detection of Cancers in Low Resource Countries
NCT01178736
Conducting Outreach to Improve Cervical Cancer Screening Rates Among Underscreened Patients
NCT02427399
Cervical Cancer Screening Intervention Among Korean American Women
NCT02594826
A Family-based Intervention to Improve Pap Test Screening Among Under-screened Chinese American Immigrant Women
NCT03961412
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Our specific aims are to:
AIM 1: Test the efficacy of tailored navigation intervention delivered by SEA community health advisors (CHA+TN) to increase age-appropriate breast and cervical cancer screening completion compared to an information and reminder only control among intergenerational SEAR/I dyads.
H1: The intervention group (CHA+TN) will have significantly higher age-appropriate breast and cervical cancer screening rates compared with the control group (information + reminder only).
AIM 2: Examine the underlying mechanisms (both mediating and moderating factors) associated with the intervention (CHA+TN) that influence breast and cervical cancer screening completion.
Exploratory AIM 3: Explore in greater detail the influence of intergenerational exchange of information between mothers and daughters related to breast and cervical cancer screening.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Control Group- Information and Reminder Only
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention Group (Navigation)
Participants will be contacted by CHAs by phone one week after giving informed consent and completion of the baseline survey. CHAs will contact participants once a week for up to 10 weeks (a maximum of 10 attempts or until a clinic appointment is made, whichever comes first). Using the TIMSĀ© message library, the CHAs will engage participants in conversations about breast and cervical cancer screening and navigate the participants to overcome any barriers to screening and motivate them to make a clinic appointment. Personal messages from mothers to daughters and vice versa and screening reminder notecards will be sent at 12-months (T3). At 18-months (T4), CHAs will follow-up with navigation group participants who reported completing a mammogram during the navigation process. Screening completion will be measured by self-report and confirmed via medical record check.
Navigation
Weekly phone-calls, personal messages, and American Cancer Society Pap test and mammography test reminder post card
Control Group (Information only)
Participants will be mailed an informational brochure on mammography and Pap testing one week after enrollment into the study. At 3-months post enrollment, CHAs will conduct a follow-up phone call with each participant to assess mammogram and/or Pap testing completion (primary outcomes). At 12-months (T3) post enrollment, CHAs will contact all control group participants by phone to confirm a scheduled appointment or screening completion. For those who completed a mammogram within the 12 months since enrollment, generic screening reminder notecards will be sent by mail. At 18-months (T4), CHAs will follow-up with those control group participants who reported scheduling a mammogram, Pap smear, or both at the 12-month (T3) time point.
Information only
American Cancer Society breast and cervical cancer screening information and Pap test and mammography test reminder post card
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Navigation
Weekly phone-calls, personal messages, and American Cancer Society Pap test and mammography test reminder post card
Information only
American Cancer Society breast and cervical cancer screening information and Pap test and mammography test reminder post card
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Self-identify as Filipino, Cambodian, Lao, or Vietnamese
* Aged 21 years and older
* Non-adherent for mammogram, Pap test, or both
* Have a mother or daughter aged 21 years and older.
* If potential participants do not have a mother or daughter, then they would have to have an immediate female family member, such as an aunt, niece, or grandmother aged 21 years and older who could also be recruited into the study.
Exclusion Criteria
* Siblings such as a sister will not be considered eligible unless they are from different generations.
21 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of South Florida
OTHER
American Cancer Society, Inc.
OTHER
Ohio State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jennifer Kue
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jennifer Kue, PhD
Role: PRINCIPAL_INVESTIGATOR
University of South Florida
Judith Tate, PhD, RN
Role: PRINCIPAL_INVESTIGATOR
Ohio State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Ohio State University
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018B0521
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.